#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Polygenic	_
1-2	10-14	risk	_
1-3	15-18	for	_
1-4	19-23	five	_
1-5	24-35	psychiatric	_
1-6	36-45	disorders	_
1-7	46-49	and	_
1-8	50-64	cross-disorder	_
1-9	65-68	and	_
1-10	69-86	disorder-specific	_
1-11	87-93	neural	_
1-12	94-106	connectivity	_
1-13	107-109	in	_
1-14	110-113	two	_
1-15	114-125	independent	_
1-16	126-137	populations	_
1-17	138-143	Major	_
1-18	144-155	psychiatric	_
1-19	156-165	disorders	_
1-20	166-167	,	_
1-21	168-177	including	_
1-22	178-187	attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-23	188-195	deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-24	196-209	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-25	210-218	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-26	219-220	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-27	221-225	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-28	226-227	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-29	228-229	,	_
1-30	230-236	autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-31	237-238	(	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-32	239-242	AUT	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-33	243-244	)	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-34	245-246	,	_
1-35	247-254	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-36	255-263	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-37	264-265	(	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-38	266-268	BD	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-39	269-270	)	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-40	271-272	,	_
1-41	273-278	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-42	279-289	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-43	290-298	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-44	299-300	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-45	301-304	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-46	305-306	)	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-47	307-308	,	_
1-48	309-312	and	_
1-49	313-326	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-50	327-328	(	_
1-51	329-331	SZ	_
1-52	332-333	)	_
1-53	334-335	,	_
1-54	336-339	are	_
1-55	340-346	highly	_
1-56	347-356	heritable	_
1-57	357-360	and	_
1-58	361-370	polygenic	_
1-59	371-372	.	_

2-1	373-381	Evidence	_
2-2	382-390	suggests	_
2-3	391-395	that	_
2-4	396-401	these	_
2-5	402-406	five	_
2-6	407-416	disorders	_
2-7	417-421	have	_
2-8	422-426	both	_
2-9	427-433	shared	_
2-10	434-437	and	_
2-11	438-446	distinct	_
2-12	447-454	genetic	_
2-13	455-460	risks	_
2-14	461-464	and	_
2-15	465-471	neural	_
2-16	472-484	connectivity	_
2-17	485-498	abnormalities	_
2-18	499-500	.	_

3-1	501-503	To	_
3-2	504-511	measure	_
3-3	512-521	aggregate	_
3-4	522-529	genetic	_
3-5	530-535	risks	_
3-6	536-537	,	_
3-7	538-541	the	_
3-8	542-551	polygenic	_
3-9	552-556	risk	_
3-10	557-562	score	_
3-11	563-564	(	_
3-12	565-569	PGRS	_
3-13	570-571	)	_
3-14	572-575	was	_
3-15	576-584	computed	_
3-16	585-586	.	_

4-1	587-590	Two	_
4-2	591-602	independent	_
4-3	603-610	general	_
4-4	611-622	populations	_
4-5	623-624	(	_
4-6	625-626	N	_
4-7	627-628	=	_
4-8	629-632	360	_
4-9	633-636	and	_
4-10	637-638	N	_
4-11	639-640	=	_
4-12	641-644	323	_
4-13	645-646	)	_
4-14	647-651	were	_
4-15	652-662	separately	_
4-16	663-671	examined	_
4-17	672-674	to	_
4-18	675-686	investigate	_
4-19	687-694	whether	_
4-20	695-698	the	_
4-21	699-713	cross-disorder	_
4-22	714-718	PGRS	_
4-23	719-722	and	_
4-24	723-727	PGRS	_
4-25	728-731	for	_
4-26	732-733	a	_
4-27	734-742	specific	_
4-28	743-751	disorder	_
4-29	752-756	were	_
4-30	757-767	associated	_
4-31	768-772	with	_
4-32	773-783	individual	_
4-33	784-795	variability	_
4-34	796-798	in	_
4-35	799-809	functional	_
4-36	810-822	connectivity	_
4-37	823-824	.	_

5-1	825-835	Consistent	_
5-2	836-843	altered	_
5-3	844-854	functional	_
5-4	855-867	connectivity	_
5-5	868-871	was	_
5-6	872-877	found	_
5-7	878-882	with	_
5-8	883-886	the	_
5-9	887-896	bilateral	_
5-10	897-903	insula	_
5-11	904-905	:	_
5-12	906-909	for	_
5-13	910-913	the	_
5-14	914-918	left	_
5-15	919-932	supplementary	_
5-16	933-938	motor	_
5-17	939-943	area	_
5-18	944-947	and	_
5-19	948-951	the	_
5-20	952-956	left	_
5-21	957-965	superior	_
5-22	966-974	temporal	_
5-23	975-980	gyrus	_
5-24	981-985	with	_
5-25	986-989	the	_
5-26	990-1004	cross-disorder	_
5-27	1005-1009	PGRS	_
5-28	1010-1011	,	_
5-29	1012-1015	for	_
5-30	1016-1019	the	_
5-31	1020-1024	left	_
5-32	1025-1031	insula	_
5-33	1032-1035	and	_
5-34	1036-1041	right	_
5-35	1042-1048	middle	_
5-36	1049-1052	and	_
5-37	1053-1061	superior	_
5-38	1062-1070	temporal	_
5-39	1071-1075	lobe	_
5-40	1076-1086	associated	_
5-41	1087-1091	with	_
5-42	1092-1095	the	_
5-43	1096-1100	PGRS	_
5-44	1101-1104	for	_
5-45	1105-1111	autism	_
5-46	1112-1113	,	_
5-47	1114-1117	for	_
5-48	1118-1121	the	_
5-49	1122-1131	bilateral	_
5-50	1132-1140	midbrain	_
5-51	1141-1142	,	_
5-52	1143-1152	posterior	_
5-53	1153-1162	cingulate	_
5-54	1163-1164	,	_
5-55	1165-1171	cuneus	_
5-56	1172-1173	,	_
5-57	1174-1177	and	_
5-58	1178-1187	precuneus	_
5-59	1188-1198	associated	_
5-60	1199-1203	with	_
5-61	1204-1207	the	_
5-62	1208-1212	PGRS	_
5-63	1213-1216	for	_
5-64	1217-1219	BD	_
5-65	1220-1221	,	_
5-66	1222-1225	and	_
5-67	1226-1229	for	_
5-68	1230-1233	the	_
5-69	1234-1238	left	_
5-70	1239-1246	angular	_
5-71	1247-1252	gyrus	_
5-72	1253-1256	and	_
5-73	1257-1260	the	_
5-74	1261-1265	left	_
5-75	1266-1278	dorsolateral	_
5-76	1279-1289	prefrontal	_
5-77	1290-1296	cortex	_
5-78	1297-1307	associated	_
5-79	1308-1312	with	_
5-80	1313-1316	the	_
5-81	1317-1321	PGRS	_
5-82	1322-1325	for	_
5-83	1326-1339	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-84	1340-1341	.	_

6-1	1342-1344	No	_
6-2	1345-1356	significant	_
6-3	1357-1367	functional	_
6-4	1368-1380	connectivity	_
6-5	1381-1384	was	_
6-6	1385-1390	found	_
6-7	1391-1401	associated	_
6-8	1402-1406	with	_
6-9	1407-1410	the	_
6-10	1411-1415	PGRS	_
6-11	1416-1419	for	_
6-12	1420-1424	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
6-13	1425-1428	and	_
6-14	1429-1432	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
6-15	1433-1434	.	_

7-1	1435-1438	Our	_
7-2	1439-1447	findings	_
7-3	1448-1457	indicated	_
7-4	1458-1462	that	_
7-5	1463-1470	genetic	_
7-6	1471-1478	effects	_
7-7	1479-1481	on	_
7-8	1482-1485	the	_
7-9	1486-1500	cross-disorder	_
7-10	1501-1504	and	_
7-11	1505-1522	disorder-specific	_
7-12	1523-1529	neural	_
7-13	1530-1542	connectivity	_
7-14	1543-1545	of	_
7-15	1546-1552	common	_
7-16	1553-1560	genetic	_
7-17	1561-1565	risk	_
7-18	1566-1570	loci	_
7-19	1571-1574	are	_
7-20	1575-1585	detectable	_
7-21	1586-1588	in	_
7-22	1589-1592	the	_
7-23	1593-1600	general	_
7-24	1601-1611	population	_
7-25	1612-1613	.	_

8-1	1614-1617	Our	_
8-2	1618-1626	findings	_
8-3	1627-1631	also	_
8-4	1632-1641	indicated	_
8-5	1642-1646	that	_
8-6	1647-1656	polygenic	_
8-7	1657-1661	risk	_
8-8	1662-1673	contributes	_
8-9	1674-1676	to	_
8-10	1677-1680	the	_
8-11	1681-1685	main	_
8-12	1686-1701	neurobiological	_
8-13	1702-1712	phenotypes	_
8-14	1713-1715	of	_
8-15	1716-1727	psychiatric	_
8-16	1728-1737	disorders	_
8-17	1738-1741	and	_
8-18	1742-1746	that	_
8-19	1747-1758	identifying	_
8-20	1759-1773	cross-disorder	_
8-21	1774-1777	and	_
8-22	1778-1786	specific	_
8-23	1787-1797	functional	_
8-24	1798-1810	connectivity	_
8-25	1811-1818	related	_
8-26	1819-1821	to	_
8-27	1822-1831	polygenic	_
8-28	1832-1837	risks	_
8-29	1838-1841	may	_
8-30	1842-1851	elucidate	_
8-31	1852-1855	the	_
8-32	1856-1862	neural	_
8-33	1863-1871	pathways	_
8-34	1872-1875	for	_
8-35	1876-1881	these	_
8-36	1882-1891	disorders	_
8-37	1892-1893	.	_

9-1	1894-1904	Highlights	_
9-2	1905-1912	Altered	_
9-3	1913-1927	cross-disorder	_
9-4	1928-1938	functional	_
9-5	1939-1951	connectivity	_
9-6	1952-1959	related	_
9-7	1960-1962	to	_
9-8	1963-1968	PGRSs	_
9-9	1969-1971	is	_
9-10	1972-1980	detected	_
9-11	1981-1982	.	_

10-1	1983-1990	Altered	_
10-2	1991-2008	disorder-specific	_
10-3	2009-2019	functional	_
10-4	2020-2032	connectivity	_
10-5	2033-2040	related	_
10-6	2041-2043	to	_
10-7	2044-2049	PGRSs	_
10-8	2050-2052	is	_
10-9	2053-2061	detected	_
10-10	2062-2063	.	_

11-1	2064-2071	Altered	_
11-2	2072-2082	functional	_
11-3	2083-2095	connectivity	_
11-4	2096-2103	related	_
11-5	2104-2106	to	_
11-6	2107-2112	PGRSs	_
11-7	2113-2115	is	_
11-8	2116-2124	involved	_
11-9	2125-2127	in	_
11-10	2128-2133	brain	_
11-11	2134-2142	networks	_
11-12	2143-2144	.	_

12-1	2145-2154	Polygenic	_
12-2	2155-2159	risk	_
12-3	2160-2171	contributes	_
12-4	2172-2174	to	_
12-5	2175-2190	neurobiological	_
12-6	2191-2201	phenotypes	_
12-7	2202-2204	of	_
12-8	2205-2216	psychiatric	_
12-9	2217-2226	disorders	_
12-10	2227-2228	.	_

13-1	2229-2238	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	2239-2242	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	2243-2250	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	2251-2263	Demographics	_
13-5	2264-2266	of	_
13-6	2267-2279	participants	_
13-7	2280-2287	Dataset	_
13-8	2288-2289	1	_
13-9	2290-2291	:	_
13-10	2292-2299	Dataset	_
13-11	2300-2301	1	_
13-12	2302-2310	included	_
13-13	2311-2314	360	_
13-14	2315-2322	healthy	_
13-15	2323-2328	young	_
13-16	2329-2336	Chinese	_
13-17	2337-2345	subjects	_
13-18	2346-2347	(	_
13-19	2348-2353	Table	_
13-20	2354-2355	1	_
13-21	2356-2357	)	_
13-22	2358-2359	.	_

14-1	2360-2363	The	_
14-2	2364-2372	subjects	_
14-3	2373-2376	and	_
14-4	2377-2382	their	_
14-5	2383-2392	relatives	_
14-6	2393-2399	within	_
14-7	2400-2403	the	_
14-8	2404-2416	third-degree	_
14-9	2417-2420	had	_
14-10	2421-2423	no	_
14-11	2424-2431	history	_
14-12	2432-2434	of	_
14-13	2435-2446	psychiatric	_
14-14	2447-2456	disorders	_
14-15	2457-2458	.	_

15-1	2459-2463	None	_
15-2	2464-2466	of	_
15-3	2467-2470	the	_
15-4	2471-2483	participants	_
15-5	2484-2487	had	_
15-6	2488-2489	a	_
15-7	2490-2497	history	_
15-8	2498-2500	of	_
15-9	2501-2512	psychiatric	_
15-10	2513-2522	treatment	_
15-11	2523-2524	,	_
15-12	2525-2529	drug	_
15-13	2530-2532	or	_
15-14	2533-2540	alcohol	_
15-15	2541-2546	abuse	_
15-16	2547-2548	,	_
15-17	2549-2558	traumatic	_
15-18	2559-2564	brain	_
15-19	2565-2571	injury	_
15-20	2572-2573	,	_
15-21	2574-2576	or	_
15-22	2577-2584	visible	_
15-23	2585-2590	brain	_
15-24	2591-2598	lesions	_
15-25	2599-2601	on	_
15-26	2602-2614	conventional	_
15-27	2615-2623	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-28	2624-2633	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-29	2634-2641	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-30	2642-2643	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-31	2644-2647	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-32	2648-2649	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-33	2650-2651	.	_

16-1	2652-2656	They	_
16-2	2657-2660	all	_
16-3	2661-2665	gave	_
16-4	2666-2670	full	_
16-5	2671-2678	written	_
16-6	2679-2687	informed	_
16-7	2688-2695	consent	_
16-8	2696-2698	to	_
16-9	2699-2703	join	_
16-10	2704-2707	the	_
16-11	2708-2713	study	_
16-12	2714-2715	.	_

17-1	2716-2719	The	_
17-2	2720-2726	Ethics	_
17-3	2727-2736	Committee	_
17-4	2737-2739	of	_
17-5	2740-2743	the	_
17-6	2744-2750	School	_
17-7	2751-2753	of	_
17-8	2754-2758	Life	_
17-9	2759-2766	Science	_
17-10	2767-2770	and	_
17-11	2771-2781	Technology	_
17-12	2782-2784	at	_
17-13	2785-2788	the	_
17-14	2789-2799	University	_
17-15	2800-2802	of	_
17-16	2803-2813	Electronic	_
17-17	2814-2821	Science	_
17-18	2822-2825	and	_
17-19	2826-2836	Technology	_
17-20	2837-2839	of	_
17-21	2840-2845	China	_
17-22	2846-2854	approved	_
17-23	2855-2859	this	_
17-24	2860-2865	study	_
17-25	2866-2867	.	_

18-1	2868-2875	Dataset	_
18-2	2876-2877	2	_
18-3	2878-2879	:	_
18-4	2880-2883	323	_
18-5	2884-2891	healthy	_
18-6	2892-2897	young	_
18-7	2898-2905	Chinese	_
18-8	2906-2914	subjects	_
18-9	2915-2919	were	_
18-10	2920-2928	included	_
18-11	2929-2931	in	_
18-12	2932-2939	Dataset	_
18-13	2940-2941	2	_
18-14	2942-2943	(	_
18-15	2944-2949	Table	_
18-16	2950-2951	1	_
18-17	2952-2953	)	_
18-18	2954-2955	.	_

19-1	2956-2960	None	_
19-2	2961-2963	of	_
19-3	2964-2967	the	_
19-4	2968-2976	subjects	_
19-5	2977-2980	nor	_
19-6	2981-2986	their	_
19-7	2987-2999	first-degree	_
19-8	3000-3009	relatives	_
19-9	3010-3013	had	_
19-10	3014-3015	a	_
19-11	3016-3023	history	_
19-12	3024-3026	of	_
19-13	3027-3038	psychiatric	_
19-14	3039-3048	diagnoses	_
19-15	3049-3050	,	_
19-16	3051-3053	of	_
19-17	3054-3066	neurological	_
19-18	3067-3069	or	_
19-19	3070-3079	metabolic	_
19-20	3080-3089	illnesses	_
19-21	3090-3091	,	_
19-22	3092-3094	or	_
19-23	3095-3097	of	_
19-24	3098-3102	drug	_
19-25	3103-3105	or	_
19-26	3106-3113	alcohol	_
19-27	3114-3119	abuse	_
19-28	3120-3121	.	_

20-1	3122-3126	They	_
20-2	3127-3130	all	_
20-3	3131-3135	gave	_
20-4	3136-3140	full	_
20-5	3141-3148	written	_
20-6	3149-3157	informed	_
20-7	3158-3165	consent	_
20-8	3166-3168	to	_
20-9	3169-3180	participate	_
20-10	3181-3183	in	_
20-11	3184-3187	the	_
20-12	3188-3193	study	_
20-13	3194-3195	.	_

21-1	3196-3199	The	_
21-2	3200-3206	Ethics	_
21-3	3207-3216	Committee	_
21-4	3217-3219	of	_
21-5	3220-3227	Tianjin	_
21-6	3228-3235	Medical	_
21-7	3236-3246	University	_
21-8	3247-3255	approved	_
21-9	3256-3260	this	_
21-10	3261-3266	study	_
21-11	3267-3268	.	_

22-1	3269-3279	Genotyping	_
22-2	3280-3283	and	_
22-3	3284-3291	quality	_
22-4	3292-3299	control	_
22-5	3300-3302	We	_
22-6	3303-3312	collected	_
22-7	3313-3318	whole	_
22-8	3319-3324	blood	_
22-9	3325-3328	and	_
22-10	3329-3338	extracted	_
22-11	3339-3346	genomic	_
22-12	3347-3350	DNA	_
22-13	3351-3356	using	_
22-14	3357-3360	the	_
22-15	3361-3367	EZgene	_
22-16	3368-3373	Blood	_
22-17	3374-3378	gDNA	_
22-18	3379-3387	Miniprep	_
22-19	3388-3391	Kit	_
22-20	3392-3395	for	_
22-21	3396-3399	all	_
22-22	3400-3408	subjects	_
22-23	3409-3410	.	_

23-1	3411-3415	Next	_
23-2	3416-3418	we	_
23-3	3419-3428	performed	_
23-4	3429-3441	whole-genome	_
23-5	3442-3452	genotyping	_
23-6	3453-3458	using	_
23-7	3459-3462	the	_
23-8	3463-3471	standard	_
23-9	3472-3480	Illumina	_
23-10	3481-3491	genotyping	_
23-11	3492-3500	protocol	_
23-12	3501-3503	on	_
23-13	3504-3512	Illumina	_
23-14	3513-3518	Human	_
23-15	3519-3533	OmniZhongHua-8	_
23-16	3534-3543	BeadChips	_
23-17	3544-3545	.	_

24-1	3546-3551	Plink	_
24-2	3552-3555	was	_
24-3	3556-3560	used	_
24-4	3561-3563	to	_
24-5	3564-3571	perform	_
24-6	3572-3579	quality	_
24-7	3580-3587	control	_
24-8	3588-3589	,	_
24-9	3590-3595	using	_
24-10	3596-3599	the	_
24-11	3600-3604	same	_
24-12	3605-3614	procedure	_
24-13	3615-3618	for	_
24-14	3619-3623	both	_
24-15	3624-3632	datasets	_
24-16	3633-3634	.	_

25-1	3635-3640	First	_
25-2	3641-3642	,	_
25-3	3643-3646	the	_
25-4	3647-3658	individuals	_
25-5	3659-3660	,	_
25-6	3661-3662	1	_
25-7	3663-3667	from	_
25-8	3668-3675	Dataset	_
25-9	3676-3677	1	_
25-10	3678-3681	and	_
25-11	3682-3683	3	_
25-12	3684-3688	from	_
25-13	3689-3696	Dataset	_
25-14	3697-3698	2	_
25-15	3699-3700	,	_
25-16	3701-3706	whose	_
25-17	3707-3714	missing	_
25-18	3715-3723	genotype	_
25-19	3724-3729	rates	_
25-20	3730-3734	were	_
25-21	3735-3736	>	_
25-22	3737-3741	0.05	_
25-23	3742-3746	were	_
25-24	3747-3755	excluded	_
25-25	3756-3757	.	_

26-1	3758-3762	Then	_
26-2	3763-3764	,	_
26-3	3765-3767	we	_
26-4	3768-3775	removed	_
26-5	3776-3779	the	_
26-6	3780-3783	one	_
26-7	3784-3788	with	_
26-8	3789-3792	the	_
26-9	3793-3800	greater	_
26-10	3801-3808	missing	_
26-11	3809-3817	genotype	_
26-12	3818-3822	rate	_
26-13	3823-3827	from	_
26-14	3828-3832	each	_
26-15	3833-3837	pair	_
26-16	3838-3842	that	_
26-17	3843-3846	had	_
26-18	3847-3851	more	_
26-19	3852-3859	similar	_
26-20	3860-3869	genotypes	_
26-21	3870-3880	identified	_
26-22	3881-3883	by	_
26-23	3884-3894	estimating	_
26-24	3895-3898	the	_
26-25	3899-3907	pairwise	_
26-26	3908-3927	identity-by-descent	_
26-27	3928-3929	(	_
26-28	3930-3933	IBD	_
26-29	3934-3935	)	_
26-30	3936-3940	than	_
26-31	3941-3943	we	_
26-32	3944-3949	would	_
26-33	3950-3954	have	_
26-34	3955-3963	expected	_
26-35	3964-3966	in	_
26-36	3967-3968	a	_
26-37	3969-3975	random	_
26-38	3976-3982	sample	_
26-39	3983-3984	,	_
26-40	3985-3993	removing	_
26-41	3994-3995	2	_
26-42	3996-4007	individuals	_
26-43	4008-4012	from	_
26-44	4013-4020	Dataset	_
26-45	4021-4022	1	_
26-46	4023-4026	and	_
26-47	4027-4028	5	_
26-48	4029-4040	individuals	_
26-49	4041-4045	from	_
26-50	4046-4053	Dataset	_
26-51	4054-4055	2	_
26-52	4056-4057	.	_

27-1	4058-4062	Next	_
27-2	4063-4064	,	_
27-3	4065-4069	SNPs	_
27-4	4070-4074	with	_
27-5	4075-4082	missing	_
27-6	4083-4091	genotype	_
27-7	4092-4097	rates	_
27-8	4098-4099	>	_
27-9	4100-4104	0.05	_
27-10	4105-4106	,	_
27-11	4107-4108	a	_
27-12	4109-4114	minor	_
27-13	4115-4121	allele	_
27-14	4122-4131	frequency	_
27-15	4132-4133	<	_
27-16	4134-4138	0.01	_
27-17	4139-4140	,	_
27-18	4141-4143	or	_
27-19	4144-4145	a	_
27-20	4146-4157	significant	_
27-21	4158-4167	departure	_
27-22	4168-4172	from	_
27-23	4173-4187	Hardy-Weinberg	_
27-24	4188-4199	Equilibrium	_
27-25	4200-4201	(	_
27-26	4202-4203	P	_
27-27	4204-4205	<	_
27-28	4206-4211	0.001	_
27-29	4212-4213	)	_
27-30	4214-4218	were	_
27-31	4219-4227	excluded	_
27-32	4228-4229	.	_

28-1	4230-4237	Finally	_
28-2	4238-4239	,	_
28-3	4240-4241	a	_
28-4	4242-4251	principal	_
28-5	4252-4261	component	_
28-6	4262-4270	analysis	_
28-7	4271-4272	(	_
28-8	4273-4276	PCA	_
28-9	4277-4278	)	_
28-10	4279-4282	was	_
28-11	4283-4292	performed	_
28-12	4293-4295	to	_
28-13	4296-4303	control	_
28-14	4304-4307	for	_
28-15	4308-4318	population	_
28-16	4319-4333	stratification	_
28-17	4334-4339	using	_
28-18	4340-4350	EIGENSTART	_
28-19	4351-4353	on	_
28-20	4354-4355	a	_
28-21	4356-4363	linkage	_
28-22	4364-4378	disequilibrium	_
28-23	4379-4380	(	_
28-24	4381-4383	LD	_
28-25	4384-4385	)	_
28-26	4386-4392	pruned	_
28-27	4393-4396	set	_
28-28	4397-4399	of	_
28-29	4400-4409	autosomal	_
28-30	4410-4414	SNPs	_
28-31	4415-4423	obtained	_
28-32	4424-4426	by	_
28-33	4427-4435	carrying	_
28-34	4436-4439	out	_
28-35	4440-4442	LD	_
28-36	4443-4450	pruning	_
28-37	4451-4455	with	_
28-38	4456-4461	PLINK	_
28-39	4462-4465	and	_
28-40	4466-4474	removing	_
28-41	4475-4476	5	_
28-42	4477-4487	long-range	_
28-43	4488-4490	LD	_
28-44	4491-4498	regions	_
28-45	4499-4503	with	_
28-46	4504-4507	the	_
28-47	4508-4514	HapMap	_
28-48	4515-4520	phase	_
28-49	4521-4522	3	_
28-50	4523-4532	reference	_
28-51	4533-4540	dataset	_
28-52	4541-4542	.	_

29-1	4543-4545	We	_
29-2	4546-4553	removed	_
29-3	4554-4557	the	_
29-4	4558-4566	outliers	_
29-5	4567-4569	of	_
29-6	4570-4573	the	_
29-7	4574-4580	sample	_
29-8	4581-4582	(	_
29-9	4583-4584	>	_
29-10	4585-4586	6	_
29-11	4587-4589	SD	_
29-12	4590-4591	)	_
29-13	4592-4597	after	_
29-14	4598-4600	we	_
29-15	4601-4611	identified	_
29-16	4612-4614	10	_
29-17	4615-4624	principle	_
29-18	4625-4635	components	_
29-19	4636-4637	.	_

30-1	4638-4639	A	_
30-2	4640-4643	Q-Q	_
30-3	4644-4648	plot	_
30-4	4649-4652	was	_
30-5	4653-4660	applied	_
30-6	4661-4664	and	_
30-7	4665-4671	showed	_
30-8	4672-4676	that	_
30-9	4677-4680	the	_
30-10	4681-4691	population	_
30-11	4692-4706	stratification	_
30-12	4707-4710	was	_
30-13	4711-4715	well	_
30-14	4716-4726	controlled	_
30-15	4727-4731	with	_
30-16	4732-4733	λ	_
30-17	4734-4735	=	_
30-18	4736-4743	1.03043	_
30-19	4744-4745	(	_
30-20	4746-4759	Supplementary	_
30-21	4760-4763	Fig	_
30-22	4764-4765	.	_

31-1	4766-4767	1	_
31-2	4768-4769	)	_
31-3	4770-4771	.	_

32-1	4772-4777	After	_
32-2	4778-4783	these	_
32-3	4784-4791	quality	_
32-4	4792-4799	control	_
32-5	4800-4810	procedures	_
32-6	4811-4812	,	_
32-7	4813-4816	356	_
32-8	4817-4820	and	_
32-9	4821-4824	311	_
32-10	4825-4833	subjects	_
32-11	4834-4846	respectively	_
32-12	4847-4849	in	_
32-13	4850-4858	Datasets	_
32-14	4859-4860	1	_
32-15	4861-4864	and	_
32-16	4865-4866	2	_
32-17	4867-4871	were	_
32-18	4872-4880	included	_
32-19	4881-4884	for	_
32-20	4885-4895	subsequent	_
32-21	4896-4904	analyses	_
32-22	4905-4906	.	_

33-1	4907-4919	Additionally	_
33-2	4920-4921	,	_
33-3	4922-4923	>	_
33-4	4924-4931	700.000	_
33-5	4932-4936	SNPs	_
33-6	4937-4945	survived	_
33-7	4946-4949	the	_
33-8	4950-4957	pruning	_
33-9	4958-4968	procedures	_
33-10	4969-4970	.	_

34-1	4971-4981	Imputation	_
34-2	4982-4985	and	_
34-3	4986-4990	PGRS	_
34-4	4991-5001	generation	_
34-5	5002-5005	The	_
34-6	5006-5012	genome	_
34-7	5013-5024	coordinates	_
34-8	5025-5029	were	_
34-9	5030-5039	converted	_
34-10	5040-5044	from	_
34-11	5045-5049	hg19	_
34-12	5050-5052	to	_
34-13	5053-5057	hg18	_
34-14	5058-5066	assembly	_
34-15	5067-5072	using	_
34-16	5073-5081	liftOver	_
34-17	5082-5083	(	_
34-18	5084-5089	https	_
34-19	5090-5091	:	_
34-20	5092-5128	//genome.ucsc.edu/cgi-bin/hgLiftOver	_
34-21	5129-5130	)	_
34-22	5131-5133	to	_
34-23	5134-5136	be	_
34-24	5137-5147	consistent	_
34-25	5148-5152	with	_
34-26	5153-5156	the	_
34-27	5157-5166	reference	_
34-28	5167-5174	dataset	_
34-29	5175-5179	used	_
34-30	5180-5182	to	_
34-31	5183-5190	perform	_
34-32	5191-5201	imputation	_
34-33	5202-5205	and	_
34-34	5206-5209	the	_
34-35	5210-5218	training	_
34-36	5219-5226	dataset	_
34-37	5227-5231	used	_
34-38	5232-5234	to	_
34-39	5235-5244	calculate	_
34-40	5245-5248	the	_
34-41	5249-5253	PGRS	_
34-42	5254-5255	.	_

35-1	5256-5267	Ungenotyped	_
35-2	5268-5272	SNPs	_
35-3	5273-5277	were	_
35-4	5278-5285	imputed	_
35-5	5286-5291	using	_
35-6	5292-5299	SHAPEIT	_
35-7	5300-5303	and	_
35-8	5304-5311	IMPUTE2	_
35-9	5312-5316	with	_
35-10	5317-5319	an	_
35-11	5320-5326	HapMap	_
35-12	5327-5332	phase	_
35-13	5333-5334	3	_
35-14	5335-5344	reference	_
35-15	5345-5352	dataset	_
35-16	5353-5354	.	_

36-1	5355-5360	After	_
36-2	5361-5371	imputation	_
36-3	5372-5373	,	_
36-4	5374-5383	1,381,116	_
36-5	5384-5388	SNPs	_
36-6	5389-5393	were	_
36-7	5394-5402	included	_
36-8	5403-5406	for	_
36-9	5407-5410	the	_
36-10	5411-5420	following	_
36-11	5421-5429	analysis	_
36-12	5430-5431	.	_

37-1	5432-5434	We	_
37-2	5435-5442	removed	_
37-3	5443-5446	the	_
37-4	5447-5451	SNPs	_
37-5	5452-5456	with	_
37-6	5457-5467	imputation	_
37-7	5468-5475	quality	_
37-8	5476-5482	scores	_
37-9	5483-5484	<	_
37-10	5485-5488	0.8	_
37-11	5489-5490	,	_
37-12	5491-5498	missing	_
37-13	5499-5507	genotype	_
37-14	5508-5513	rates	_
37-15	5514-5515	>	_
37-16	5516-5520	0.05	_
37-17	5521-5522	,	_
37-18	5523-5524	a	_
37-19	5525-5530	minor	_
37-20	5531-5537	allele	_
37-21	5538-5547	frequency	_
37-22	5548-5549	<	_
37-23	5550-5554	0.01	_
37-24	5555-5556	,	_
37-25	5557-5559	or	_
37-26	5560-5571	significant	_
37-27	5572-5581	departure	_
37-28	5582-5586	from	_
37-29	5587-5601	Hardy-Weinberg	_
37-30	5602-5613	Equilibrium	_
37-31	5614-5615	(	_
37-32	5616-5617	P	_
37-33	5618-5619	<	_
37-34	5620-5626	0.0001	_
37-35	5627-5628	)	_
37-36	5629-5630	.	_

38-1	5631-5636	About	_
38-2	5637-5644	960,000	_
38-3	5645-5649	SNPs	_
38-4	5650-5658	survived	_
38-5	5659-5662	the	_
38-6	5663-5670	pruning	_
38-7	5671-5681	procedures	_
38-8	5682-5685	and	_
38-9	5686-5690	were	_
38-10	5691-5695	used	_
38-11	5696-5698	to	_
38-12	5699-5708	calculate	_
38-13	5709-5712	the	_
38-14	5713-5718	PGRSs	_
38-15	5719-5720	.	_

39-1	5721-5724	The	_
39-2	5725-5729	GWAS	_
39-3	5730-5734	data	_
39-4	5735-5739	used	_
39-5	5740-5742	to	_
39-6	5743-5752	calculate	_
39-7	5753-5756	the	_
39-8	5757-5761	PGRS	_
39-9	5762-5765	was	_
39-10	5766-5772	pruned	_
39-11	5773-5776	for	_
39-12	5777-5784	linkage	_
39-13	5785-5799	disequilibrium	_
39-14	5800-5801	(	_
39-15	5802-5804	r2	_
39-16	5805-5806	<	_
39-17	5807-5811	0.25	_
39-18	5812-5813	)	_
39-19	5814-5816	at	_
39-20	5817-5827	thresholds	_
39-21	5828-5830	of	_
39-22	5831-5833	PT	_
39-23	5834-5835	<	_
39-24	5836-5840	0.01	_
39-25	5841-5842	,	_
39-26	5843-5845	PT	_
39-27	5846-5847	<	_
39-28	5848-5852	0.05	_
39-29	5853-5854	,	_
39-30	5855-5857	PT	_
39-31	5858-5859	<	_
39-32	5860-5863	0.1	_
39-33	5864-5867	and	_
39-34	5868-5870	PT	_
39-35	5871-5872	<	_
39-36	5873-5876	0.5	_
39-37	5877-5878	.	_

40-1	5879-5881	It	_
40-2	5882-5884	is	_
40-3	5885-5894	important	_
40-4	5895-5897	to	_
40-5	5898-5904	choose	_
40-6	5905-5907	an	_
40-7	5908-5919	appropriate	_
40-8	5920-5931	P-threshold	_
40-9	5932-5934	to	_
40-10	5935-5941	define	_
40-11	5942-5946	PGRS	_
40-12	5947-5950	and	_
40-13	5951-5958	methods	_
40-14	5959-5962	are	_
40-15	5963-5971	proposed	_
40-16	5972-5974	to	_
40-17	5975-5981	choose	_
40-18	5982-5985	the	_
40-19	5986-5995	threshold	_
40-20	5996-5997	.	_

41-1	5998-6005	However	_
41-2	6006-6007	,	_
41-3	6008-6013	since	_
41-4	6014-6018	this	_
41-5	6019-6021	is	_
41-6	6022-6023	a	_
41-7	6024-6028	data	_
41-8	6029-6035	driven	_
41-9	6036-6041	study	_
41-10	6042-6049	without	_
41-11	6050-6060	predefined	_
41-12	6061-6071	phenotypes	_
41-13	6072-6073	,	_
41-14	6074-6078	this	_
41-15	6079-6085	method	_
41-16	6086-6091	could	_
41-17	6092-6095	not	_
41-18	6096-6100	work	_
41-19	6101-6103	on	_
41-20	6104-6107	our	_
41-21	6108-6113	study	_
41-22	6114-6115	.	_

42-1	6116-6117	A	_
42-2	6118-6122	more	_
42-3	6123-6132	stringent	_
42-4	6133-6142	threshold	_
42-5	6143-6152	generates	_
42-6	6153-6154	a	_
42-7	6155-6158	SNP	_
42-8	6159-6162	set	_
42-9	6163-6167	with	_
42-10	6168-6172	less	_
42-11	6173-6177	SNPs	_
42-12	6178-6183	being	_
42-13	6184-6189	truly	_
42-14	6190-6200	associated	_
42-15	6201-6205	with	_
42-16	6206-6209	the	_
42-17	6210-6219	disorders	_
42-18	6220-6221	.	_

43-1	6222-6226	With	_
43-2	6227-6228	a	_
43-3	6229-6233	more	_
43-4	6234-6241	liberal	_
43-5	6242-6251	threshold	_
43-6	6252-6253	,	_
43-7	6254-6258	more	_
43-8	6259-6263	SNPs	_
43-9	6264-6268	will	_
43-10	6269-6271	be	_
43-11	6272-6280	included	_
43-12	6281-6282	,	_
43-13	6283-6288	which	_
43-14	6289-6293	will	_
43-15	6294-6298	help	_
43-16	6299-6307	increase	_
43-17	6308-6311	the	_
43-18	6312-6323	statistical	_
43-19	6324-6329	power	_
43-20	6330-6331	.	_

44-1	6332-6335	But	_
44-2	6336-6339	too	_
44-3	6340-6347	liberal	_
44-4	6348-6357	threshold	_
44-5	6358-6362	will	_
44-6	6363-6370	include	_
44-7	6371-6375	SNPs	_
44-8	6376-6380	that	_
44-9	6381-6384	are	_
44-10	6385-6388	too	_
44-11	6389-6395	weakly	_
44-12	6396-6406	associated	_
44-13	6407-6411	with	_
44-14	6412-6415	the	_
44-15	6416-6425	disorders	_
44-16	6426-6427	.	_

45-1	6428-6430	So	_
45-2	6431-6434	the	_
45-3	6435-6446	statistical	_
45-4	6447-6452	power	_
45-5	6453-6457	will	_
45-6	6458-6466	decrease	_
45-7	6467-6468	.	_

46-1	6469-6474	Among	_
46-2	6475-6480	these	_
46-3	6481-6485	four	_
46-4	6486-6496	thresholds	_
46-5	6497-6498	,	_
46-6	6499-6501	PT	_
46-7	6502-6503	<	_
46-8	6504-6508	0.05	_
46-9	6509-6514	could	_
46-10	6515-6517	be	_
46-11	6518-6519	a	_
46-12	6520-6527	balance	_
46-13	6528-6530	of	_
46-14	6531-6542	statistical	_
46-15	6543-6548	power	_
46-16	6549-6552	and	_
46-17	6553-6556	the	_
46-18	6557-6563	number	_
46-19	6564-6566	of	_
46-20	6567-6571	SNPs	_
46-21	6572-6573	.	_

47-1	6574-6576	So	_
47-2	6577-6580	our	_
47-3	6581-6589	research	_
47-4	6590-6593	was	_
47-5	6594-6603	primarily	_
47-6	6604-6609	based	_
47-7	6610-6612	on	_
47-8	6613-6616	the	_
47-9	6617-6621	PGRS	_
47-10	6622-6632	calculated	_
47-11	6633-6635	at	_
47-12	6636-6638	PT	_
47-13	6639-6640	<	_
47-14	6641-6645	0.05	_
47-15	6646-6647	,	_
47-16	6648-6651	and	_
47-17	6652-6654	we	_
47-18	6655-6663	analyzed	_
47-19	6664-6668	PGRS	_
47-20	6669-6671	at	_
47-21	6672-6677	other	_
47-22	6678-6688	thresholds	_
47-23	6689-6694	based	_
47-24	6695-6697	on	_
47-25	6698-6701	the	_
47-26	6702-6709	results	_
47-27	6710-6712	of	_
47-28	6713-6715	PT	_
47-29	6716-6717	<	_
47-30	6718-6722	0.05	_
47-31	6723-6724	.	_

48-1	6725-6727	We	_
48-2	6728-6738	calculated	_
48-3	6739-6742	the	_
48-4	6743-6747	PGRS	_
48-5	6748-6753	using	_
48-6	6754-6757	the	_
48-7	6758-6764	method	_
48-8	6765-6774	described	_
48-9	6775-6777	in	_
48-10	6778-6779	a	_
48-11	6780-6788	previous	_
48-12	6789-6794	paper	_
48-13	6795-6796	.	_

49-1	6797-6802	First	_
49-2	6803-6805	we	_
49-3	6806-6816	calculated	_
49-4	6817-6820	the	_
49-5	6821-6835	cross-disorder	_
49-6	6836-6841	PGRSs	_
49-7	6842-6845	and	_
49-8	6846-6850	then	_
49-9	6851-6861	calculated	_
49-10	6862-6867	PGRSs	_
49-11	6868-6871	for	_
49-12	6872-6876	each	_
49-13	6877-6879	of	_
49-14	6880-6885	these	_
49-15	6886-6890	five	_
49-16	6891-6900	disorders	_
49-17	6901-6902	(	_
49-18	6903-6907	ADHD	_
49-19	6908-6909	,	_
49-20	6910-6916	autism	_
49-21	6917-6918	,	_
49-22	6919-6921	BD	_
49-23	6922-6923	,	_
49-24	6924-6927	MDD	_
49-25	6928-6929	,	_
49-26	6930-6943	schizophrenia	_
49-27	6944-6945	)	_
49-28	6946-6956	separately	_
49-29	6957-6958	.	_

50-1	6959-6962	The	_
50-2	6963-6970	summary	_
50-3	6971-6975	GWAS	_
50-4	6976-6983	results	_
50-5	6984-6988	from	_
50-6	6989-6992	the	_
50-7	6993-6996	PGC	_
50-8	6997-7001	GWAS	_
50-9	7002-7007	Cross	_
50-10	7008-7016	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
50-11	7017-7022	group	_
50-12	7023-7027	were	_
50-13	7028-7032	used	_
50-14	7033-7035	as	_
50-15	7036-7044	training	_
50-16	7045-7053	datasets	_
50-17	7054-7055	.	_

51-1	7056-7060	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
51-2	7061-7066	image	_
51-3	7067-7078	acquisition	_
51-4	7079-7082	and	_
51-5	7083-7096	preprocessing	_
51-6	7097-7100	The	_
51-7	7101-7106	image	_
51-8	7107-7118	acquisition	_
51-9	7119-7123	from	_
51-10	7124-7128	each	_
51-11	7129-7136	scanner	_
51-12	7137-7140	was	_
51-13	7141-7149	finished	_
51-14	7150-7156	within	_
51-15	7157-7160	six	_
51-16	7161-7167	months	_
51-17	7168-7169	.	_

52-1	7170-7175	There	_
52-2	7176-7180	were	_
52-3	7181-7183	no	_
52-4	7184-7192	hardware	_
52-5	7193-7195	or	_
52-6	7196-7202	system	_
52-7	7203-7211	upgrades	_
52-8	7212-7215	for	_
52-9	7216-7222	either	_
52-10	7223-7230	scanner	_
52-11	7231-7232	,	_
52-12	7233-7236	and	_
52-13	7237-7240	the	_
52-14	7241-7249	sequence	_
52-15	7250-7253	and	_
52-16	7254-7263	protocols	_
52-17	7264-7267	for	_
52-18	7268-7272	each	_
52-19	7273-7280	subject	_
52-20	7281-7285	were	_
52-21	7286-7290	kept	_
52-22	7291-7299	constant	_
52-23	7300-7302	in	_
52-24	7303-7307	each	_
52-25	7308-7316	scanning	_
52-26	7317-7323	period	_
52-27	7324-7325	.	_

53-1	7326-7329	The	_
53-2	7330-7338	subjects	_
53-3	7339-7343	from	_
53-4	7344-7351	Dataset	_
53-5	7352-7353	1	_
53-6	7354-7358	were	_
53-7	7359-7366	scanned	_
53-8	7367-7369	on	_
53-9	7370-7371	a	_
53-10	7372-7377	MR750	_
53-11	7378-7382	3.0T	_
53-12	7383-7391	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
53-13	7392-7401	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
53-14	7402-7409	scanner	_
53-15	7410-7411	(	_
53-16	7412-7414	GE	_
53-17	7415-7425	Healthcare	_
53-18	7426-7427	,	_
53-19	7428-7437	Milwaukee	_
53-20	7438-7439	,	_
53-21	7440-7442	WI	_
53-22	7443-7444	)	_
53-23	7445-7446	.	_

54-1	7447-7460	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
54-2	7461-7471	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
54-3	7472-7479	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
54-4	7480-7484	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
54-5	7485-7488	was	_
54-6	7489-7497	obtained	_
54-7	7498-7503	using	_
54-8	7504-7505	a	_
54-9	7506-7519	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
54-10	7520-7539	echo-planar-imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
54-11	7540-7541	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
54-12	7542-7549	GRE-EPI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
54-13	7550-7551	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
54-14	7552-7560	sequence	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
54-15	7561-7565	with	_
54-16	7566-7569	the	_
54-17	7570-7579	following	_
54-18	7580-7593	configuration	_
54-19	7594-7595	:	_
54-20	7596-7600	echo	_
54-21	7601-7605	time	_
54-22	7606-7607	(	_
54-23	7608-7610	TE	_
54-24	7611-7612	)	_
54-25	7613-7614	=	_
54-26	7615-7617	30	_
54-27	7618-7620	ms	_
54-28	7621-7622	,	_
54-29	7623-7633	repetition	_
54-30	7634-7638	time	_
54-31	7639-7640	(	_
54-32	7641-7643	TR	_
54-33	7644-7645	)	_
54-34	7646-7647	=	_
54-35	7648-7652	2000	_
54-36	7653-7655	ms	_
54-37	7656-7657	,	_
54-38	7658-7662	flip	_
54-39	7663-7668	angle	_
54-40	7669-7670	=	_
54-41	7671-7674	90°	_
54-42	7675-7676	,	_
54-43	7677-7682	field	_
54-44	7683-7685	of	_
54-45	7686-7690	view	_
54-46	7691-7692	(	_
54-47	7693-7696	FOV	_
54-48	7697-7698	)	_
54-49	7699-7700	=	_
54-50	7701-7704	240	_
54-51	7705-7706	×	_
54-52	7707-7710	240	_
54-53	7711-7714	mm2	_
54-54	7715-7716	,	_
54-55	7717-7723	matrix	_
54-56	7724-7725	=	_
54-57	7726-7728	64	_
54-58	7729-7730	×	_
54-59	7731-7733	64	_
54-60	7734-7735	,	_
54-61	7736-7741	voxel	_
54-62	7742-7746	size	_
54-63	7747-7748	=	_
54-64	7749-7753	3.75	_
54-65	7754-7755	×	_
54-66	7756-7760	3.75	_
54-67	7761-7762	×	_
54-68	7763-7767	4.00	_
54-69	7768-7771	mm3	_
54-70	7772-7773	,	_
54-71	7774-7776	39	_
54-72	7777-7783	slices	_
54-73	7784-7787	and	_
54-74	7788-7791	255	_
54-75	7792-7799	volumes	_
54-76	7800-7801	.	_

55-1	7802-7805	The	_
55-2	7806-7814	subjects	_
55-3	7815-7819	from	_
55-4	7820-7827	Dataset	_
55-5	7828-7829	2	_
55-6	7830-7834	were	_
55-7	7835-7842	scanned	_
55-8	7843-7848	using	_
55-9	7849-7850	a	_
55-10	7851-7856	Signa	_
55-11	7857-7860	HDx	_
55-12	7861-7865	3.0T	_
55-13	7866-7873	scanner	_
55-14	7874-7875	(	_
55-15	7876-7878	GE	_
55-16	7879-7889	Healthcare	_
55-17	7890-7891	,	_
55-18	7892-7901	Milwaukee	_
55-19	7902-7903	,	_
55-20	7904-7906	WI	_
55-21	7907-7908	)	_
55-22	7909-7910	.	_

56-1	7911-7913	We	_
56-2	7914-7918	used	_
56-3	7919-7920	a	_
56-4	7921-7932	single-shot	_
56-5	7933-7946	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-6	7947-7958	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-7	7959-7966	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-8	7967-7968	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-9	7969-7979	SS-GRE-EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-10	7980-7981	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-11	7982-7990	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
56-12	7991-7993	to	_
56-13	7994-8001	perform	_
56-14	8002-8015	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
56-15	8016-8026	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
56-16	8027-8034	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
56-17	8035-8039	with	_
56-18	8040-8043	the	_
56-19	8044-8053	following	_
56-20	8054-8064	parameters	_
56-21	8065-8066	:	_
56-22	8067-8077	repetition	_
56-23	8078-8082	time	_
56-24	8083-8084	(	_
56-25	8085-8087	TR	_
56-26	8088-8089	)	_
56-27	8090-8091	=	_
56-28	8092-8096	2000	_
56-29	8097-8099	ms	_
56-30	8100-8101	,	_
56-31	8102-8106	echo	_
56-32	8107-8111	time	_
56-33	8112-8113	(	_
56-34	8114-8116	TE	_
56-35	8117-8118	)	_
56-36	8119-8120	=	_
56-37	8121-8123	30	_
56-38	8124-8126	ms	_
56-39	8127-8128	,	_
56-40	8129-8134	field	_
56-41	8135-8137	of	_
56-42	8138-8142	view	_
56-43	8143-8144	(	_
56-44	8145-8148	FOV	_
56-45	8149-8150	)	_
56-46	8151-8152	=	_
56-47	8153-8156	240	_
56-48	8157-8158	×	_
56-49	8159-8162	240	_
56-50	8163-8166	mm2	_
56-51	8167-8168	,	_
56-52	8169-8175	matrix	_
56-53	8176-8177	=	_
56-54	8178-8180	64	_
56-55	8181-8182	×	_
56-56	8183-8185	64	_
56-57	8186-8187	,	_
56-58	8188-8192	flip	_
56-59	8193-8198	angle	_
56-60	8199-8200	=	_
56-61	8201-8204	90°	_
56-62	8205-8206	,	_
56-63	8207-8212	voxel	_
56-64	8213-8217	size	_
56-65	8218-8219	=	_
56-66	8220-8224	3.75	_
56-67	8225-8226	×	_
56-68	8227-8231	3.75	_
56-69	8232-8233	×	_
56-70	8234-8238	4.00	_
56-71	8239-8242	mm3	_
56-72	8243-8244	,	_
56-73	8245-8247	40	_
56-74	8248-8254	slices	_
56-75	8255-8256	,	_
56-76	8257-8260	and	_
56-77	8261-8264	180	_
56-78	8265-8272	volumes	_
56-79	8273-8274	.	_

57-1	8275-8278	All	_
57-2	8279-8291	participants	_
57-3	8292-8296	were	_
57-4	8297-8302	asked	_
57-5	8303-8305	to	_
57-6	8306-8311	close	_
57-7	8312-8317	their	_
57-8	8318-8322	eyes	_
57-9	8323-8326	and	_
57-10	8327-8332	avoid	_
57-11	8333-8341	movement	_
57-12	8342-8343	,	_
57-13	8344-8349	think	_
57-14	8350-8355	about	_
57-15	8356-8363	nothing	_
57-16	8364-8366	in	_
57-17	8367-8377	particular	_
57-18	8378-8379	,	_
57-19	8380-8383	and	_
57-20	8384-8389	avoid	_
57-21	8390-8398	sleeping	_
57-22	8399-8400	.	_

58-1	8401-8406	After	_
58-2	8407-8415	scanning	_
58-3	8416-8417	,	_
58-4	8418-8421	the	_
58-5	8422-8430	subjects	_
58-6	8431-8435	were	_
58-7	8436-8441	asked	_
58-8	8442-8444	if	_
58-9	8445-8449	they	_
58-10	8450-8454	fell	_
58-11	8455-8461	asleep	_
58-12	8462-8464	to	_
58-13	8465-8471	ensure	_
58-14	8472-8476	that	_
58-15	8477-8481	they	_
58-16	8482-8485	had	_
58-17	8486-8489	all	_
58-18	8490-8498	remained	_
58-19	8499-8504	awake	_
58-20	8505-8506	.	_

59-1	8507-8510	The	_
59-2	8511-8515	same	_
59-3	8516-8529	preprocessing	_
59-4	8530-8540	procedures	_
59-5	8541-8545	were	_
59-6	8546-8553	applied	_
59-7	8554-8556	to	_
59-8	8557-8561	each	_
59-9	8562-8569	dataset	_
59-10	8570-8571	,	_
59-11	8572-8575	and	_
59-12	8576-8583	DPARSFA	_
59-13	8584-8585	(	_
59-14	8586-8590	Data	_
59-15	8591-8601	Processing	_
59-16	8602-8611	Assistant	_
59-17	8612-8615	for	_
59-18	8616-8623	Resting	_
59-19	8624-8629	State	_
59-20	8630-8634	fMRI	_
59-21	8635-8643	Advanced	_
59-22	8644-8651	Edition	_
59-23	8652-8653	,	_
59-24	8654-8658	http	_
59-25	8659-8660	:	_
59-26	8661-8692	//www.restfmri.net/forum/DPARSF	_
59-27	8693-8694	)	_
59-28	8695-8698	was	_
59-29	8699-8703	used	_
59-30	8704-8706	to	_
59-31	8707-8717	preprocess	_
59-32	8718-8721	the	_
59-33	8722-8728	images	_
59-34	8729-8730	.	_

60-1	8731-8734	The	_
60-2	8735-8748	preprocessing	_
60-3	8749-8759	procedures	_
60-4	8760-8768	included	_
60-5	8769-8770	:	_
60-6	8771-8772	(	_
60-7	8773-8774	1	_
60-8	8775-8776	)	_
60-9	8777-8785	removing	_
60-10	8786-8789	the	_
60-11	8790-8795	first	_
60-12	8796-8798	10	_
60-13	8799-8806	volumes	_
60-14	8807-8808	;	_
60-15	8809-8810	(	_
60-16	8811-8812	2	_
60-17	8813-8814	)	_
60-18	8815-8820	slice	_
60-19	8821-8827	timing	_
60-20	8828-8829	;	_
60-21	8830-8831	(	_
60-22	8832-8833	3	_
60-23	8834-8835	)	_
60-24	8836-8840	head	_
60-25	8841-8847	motion	_
60-26	8848-8858	correction	_
60-27	8859-8860	;	_
60-28	8861-8862	(	_
60-29	8863-8864	4	_
60-30	8865-8866	)	_
60-31	8867-8874	spatial	_
60-32	8875-8888	normalization	_
60-33	8889-8890	;	_
60-34	8891-8892	(	_
60-35	8893-8894	5	_
60-36	8895-8896	)	_
60-37	8897-8906	smoothing	_
60-38	8907-8911	with	_
60-39	8912-8913	a	_
60-40	8914-8915	6	_
60-41	8916-8918	mm	_
60-42	8919-8927	Gaussian	_
60-43	8928-8934	kernel	_
60-44	8935-8936	;	_
60-45	8937-8938	(	_
60-46	8939-8940	6	_
60-47	8941-8942	)	_
60-48	8943-8951	removing	_
60-49	8952-8955	the	_
60-50	8956-8965	influence	_
60-51	8966-8968	of	_
60-52	8969-8972	the	_
60-53	8973-8978	whole	_
60-54	8979-8984	brain	_
60-55	8985-8992	signals	_
60-56	8993-8994	,	_
60-57	8995-8999	head	_
60-58	9000-9007	motions	_
60-59	9008-9009	,	_
60-60	9010-9013	and	_
60-61	9014-9020	linear	_
60-62	9021-9027	trends	_
60-63	9028-9029	;	_
60-64	9030-9033	and	_
60-65	9034-9035	(	_
60-66	9036-9037	7	_
60-67	9038-9039	)	_
60-68	9040-9048	temporal	_
60-69	9049-9058	band-pass	_
60-70	9059-9069	filtration	_
60-71	9070-9071	(	_
60-72	9072-9081	0.01–0.08	_
60-73	9082-9084	HZ	_
60-74	9085-9086	)	_
60-75	9087-9088	.	_

61-1	9089-9094	After	_
61-2	9095-9108	preprocessing	_
61-3	9109-9110	,	_
61-4	9111-9113	28	_
61-5	9114-9117	and	_
61-6	9118-9120	14	_
61-7	9121-9129	subjects	_
61-8	9130-9142	respectively	_
61-9	9143-9147	from	_
61-10	9148-9156	Datasets	_
61-11	9157-9158	1	_
61-12	9159-9162	and	_
61-13	9163-9164	2	_
61-14	9165-9169	were	_
61-15	9170-9178	excluded	_
61-16	9179-9182	due	_
61-17	9183-9185	to	_
61-18	9186-9187	a	_
61-19	9188-9195	maximum	_
61-20	9196-9208	displacement	_
61-21	9209-9210	>	_
61-22	9211-9212	2	_
61-23	9213-9215	mm	_
61-24	9216-9218	or	_
61-25	9219-9220	a	_
61-26	9221-9225	spin	_
61-27	9226-9227	>	_
61-28	9228-9230	2°	_
61-29	9231-9233	in	_
61-30	9234-9237	any	_
61-31	9238-9240	of	_
61-32	9241-9244	the	_
61-33	9245-9253	cardinal	_
61-34	9254-9264	directions	_
61-35	9265-9266	.	_

62-1	9267-9270	ROI	_
62-2	9271-9281	definition	_
62-3	9282-9287	Since	_
62-4	9288-9302	cross-disorder	_
62-5	9303-9307	PGRS	_
62-6	9308-9317	indicates	_
62-7	9318-9324	shared	_
62-8	9325-9332	genetic	_
62-9	9333-9338	risks	_
62-10	9339-9342	for	_
62-11	9343-9348	these	_
62-12	9349-9353	five	_
62-13	9354-9365	psychiatric	_
62-14	9366-9375	disorders	_
62-15	9376-9377	,	_
62-16	9378-9383	brain	_
62-17	9384-9391	regions	_
62-18	9392-9396	that	_
62-19	9397-9403	showed	_
62-20	9404-9414	disruption	_
62-21	9415-9417	in	_
62-22	9418-9421	all	_
62-23	9422-9426	five	_
62-24	9427-9432	major	_
62-25	9433-9444	psychiatric	_
62-26	9445-9454	disorders	_
62-27	9455-9459	were	_
62-28	9460-9466	chosen	_
62-29	9467-9469	as	_
62-30	9470-9471	a	_
62-31	9472-9475	ROI	_
62-32	9476-9478	to	_
62-33	9479-9490	investigate	_
62-34	9491-9494	the	_
62-35	9495-9507	associations	_
62-36	9508-9515	between	_
62-37	9516-9526	functional	_
62-38	9527-9539	connectivity	_
62-39	9540-9543	and	_
62-40	9544-9558	cross-disorder	_
62-41	9559-9563	PGRS	_
62-42	9564-9567	and	_
62-43	9568-9581	contributions	_
62-44	9582-9584	of	_
62-45	9585-9594	subscores	_
62-46	9595-9598	for	_
62-47	9599-9603	each	_
62-48	9604-9606	of	_
62-49	9607-9612	these	_
62-50	9613-9617	five	_
62-51	9618-9627	disorders	_
62-52	9628-9630	to	_
62-53	9631-9634	the	_
62-54	9635-9649	cross-disorder	_
62-55	9650-9657	impacts	_
62-56	9658-9663	using	_
62-57	9664-9677	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
62-58	9678-9682	fMRI	_
62-59	9683-9684	.	_

63-1	9685-9687	We	_
63-2	9688-9692	used	_
63-3	9693-9704	statistical	_
63-4	9705-9714	inference	_
63-5	9715-9719	maps	_
63-6	9720-9728	acquired	_
63-7	9729-9733	from	_
63-8	9734-9744	Neurosynth	_
63-9	9745-9746	(	_
63-10	9747-9751	http	_
63-11	9752-9753	:	_
63-12	9754-9771	//neurosynth.org/	_
63-13	9772-9773	)	_
63-14	9774-9776	to	_
63-15	9777-9783	define	_
63-16	9784-9787	the	_
63-17	9788-9794	region	_
63-18	9795-9797	of	_
63-19	9798-9806	interest	_
63-20	9807-9808	(	_
63-21	9809-9812	ROI	_
63-22	9813-9814	)	_
63-23	9815-9818	for	_
63-24	9819-9826	further	_
63-25	9827-9837	functional	_
63-26	9838-9850	connectivity	_
63-27	9851-9859	analysis	_
63-28	9860-9861	.	_

64-1	9862-9864	We	_
64-2	9865-9873	searched	_
64-3	9874-9877	the	_
64-4	9878-9891	meta-analysis	_
64-5	9892-9899	results	_
64-6	9900-9904	from	_
64-7	9905-9915	Neurosynth	_
64-8	9916-9917	(	_
64-9	9918-9922	http	_
64-10	9923-9924	:	_
64-11	9925-9942	//neurosynth.org/	_
64-12	9943-9944	)	_
64-13	9945-9948	for	_
64-14	9949-9952	the	_
64-15	9953-9954	5	_
64-16	9955-9960	major	_
64-17	9961-9972	psychiatric	_
64-18	9973-9982	disorders	_
64-19	9983-9984	,	_
64-20	9985-9995	separately	_
64-21	9996-10001	using	_
64-22	10002-10006	ADHD	_
64-23	10007-10008	,	_
64-24	10009-10015	autism	_
64-25	10016-10017	,	_
64-26	10018-10025	bipolar	_
64-27	10026-10027	,	_
64-28	10028-10038	depression	_
64-29	10039-10040	,	_
64-30	10041-10044	and	_
64-31	10045-10058	schizophrenia	_
64-32	10059-10061	as	_
64-33	10062-10068	search	_
64-34	10069-10074	terms	_
64-35	10075-10076	.	_

65-1	10077-10079	If	_
65-2	10080-10081	a	_
65-3	10082-10087	study	_
65-4	10088-10092	used	_
65-5	10093-10096	one	_
65-6	10097-10099	of	_
65-7	10100-10103	the	_
65-8	10104-10112	searched	_
65-9	10113-10121	keywords	_
65-10	10122-10123	,	_
65-11	10124-10126	we	_
65-12	10127-10135	obtained	_
65-13	10136-10147	statistical	_
65-14	10148-10157	inference	_
65-15	10158-10162	maps	_
65-16	10163-10173	displaying	_
65-17	10174-10182	z-scores	_
65-18	10183-10192	according	_
65-19	10193-10195	to	_
65-20	10196-10199	the	_
65-21	10200-10211	probability	_
65-22	10212-10214	of	_
65-23	10215-10216	a	_
65-24	10217-10223	region	_
65-25	10224-10226	's	_
65-26	10227-10232	being	_
65-27	10233-10242	activated	_
65-28	10243-10244	.	_

66-1	10245-10247	In	_
66-2	10248-10253	other	_
66-3	10254-10259	words	_
66-4	10260-10261	,	_
66-5	10262-10267	these	_
66-6	10268-10272	maps	_
66-7	10273-10282	displayed	_
66-8	10283-10286	the	_
66-9	10287-10292	brain	_
66-10	10293-10300	regions	_
66-11	10301-10305	that	_
66-12	10306-10310	were	_
66-13	10311-10323	consistently	_
66-14	10324-10333	activated	_
66-15	10334-10336	in	_
66-16	10337-10344	studies	_
66-17	10345-10349	that	_
66-18	10350-10356	loaded	_
66-19	10357-10363	highly	_
66-20	10364-10366	on	_
66-21	10367-10368	a	_
66-22	10369-10377	specific	_
66-23	10378-10382	term	_
66-24	10383-10384	.	_

67-1	10385-10386	A	_
67-2	10387-10392	large	_
67-3	10393-10400	z-score	_
67-4	10401-10406	means	_
67-5	10407-10411	that	_
67-6	10412-10416	this	_
67-7	10417-10423	region	_
67-8	10424-10427	was	_
67-9	10428-10436	reported	_
67-10	10437-10441	more	_
67-11	10442-10447	often	_
67-12	10448-10452	than	_
67-13	10453-10464	expectation	_
67-14	10465-10470	under	_
67-15	10471-10474	the	_
67-16	10475-10485	hypothesis	_
67-17	10486-10490	that	_
67-18	10491-10502	activations	_
67-19	10503-10505	in	_
67-20	10506-10509	the	_
67-21	10510-10515	brain	_
67-22	10516-10521	would	_
67-23	10522-10524	be	_
67-24	10525-10532	equally	_
67-25	10533-10539	likely	_
67-26	10540-10541	.	_

68-1	10542-10547	These	_
68-2	10548-10552	maps	_
68-3	10553-10557	were	_
68-4	10558-10569	thresholded	_
68-5	10570-10572	at	_
68-6	10573-10574	a	_
68-7	10575-10580	false	_
68-8	10581-10590	discovery	_
68-9	10591-10595	rate	_
68-10	10596-10597	(	_
68-11	10598-10601	FDR	_
68-12	10602-10603	)	_
68-13	10604-10606	of	_
68-14	10607-10611	0.01	_
68-15	10612-10613	(	_
68-16	10614-10617	Fig	_
68-17	10618-10619	.	_

69-1	10620-10621	1	_
69-2	10622-10623	)	_
69-3	10624-10625	.	_

70-1	10626-10629	The	_
70-2	10630-10635	brain	_
70-3	10636-10643	regions	_
70-4	10644-10652	affected	_
70-5	10653-10655	by	_
70-6	10656-10659	all	_
70-7	10660-10661	5	_
70-8	10662-10671	disorders	_
70-9	10672-10676	were	_
70-10	10677-10684	defined	_
70-11	10685-10687	as	_
70-12	10688-10690	an	_
70-13	10691-10694	ROI	_
70-14	10695-10696	.	_

71-1	10697-10701	This	_
71-2	10702-10705	ROI	_
71-3	10706-10715	primarily	_
71-4	10716-10724	included	_
71-5	10725-10728	the	_
71-6	10729-10738	bilateral	_
71-7	10739-10745	insula	_
71-8	10746-10747	,	_
71-9	10748-10753	which	_
71-10	10754-10756	is	_
71-11	10757-10767	reasonable	_
71-12	10768-10773	since	_
71-13	10774-10777	the	_
71-14	10778-10785	insulae	_
71-15	10786-10790	have	_
71-16	10791-10795	been	_
71-17	10796-10805	suggested	_
71-18	10806-10808	as	_
71-19	10809-10814	being	_
71-20	10815-10823	affected	_
71-21	10824-10826	by	_
71-22	10827-10830	all	_
71-23	10831-10835	five	_
71-24	10836-10841	major	_
71-25	10842-10853	psychiatric	_
71-26	10854-10863	disorders	_
71-27	10864-10865	.	_

72-1	10866-10870	Then	_
72-2	10871-10873	we	_
72-3	10874-10883	resampled	_
72-4	10884-10887	the	_
72-5	10888-10893	voxel	_
72-6	10894-10898	size	_
72-7	10899-10901	of	_
72-8	10902-10905	the	_
72-9	10906-10909	ROI	_
72-10	10910-10912	to	_
72-11	10913-10914	3	_
72-12	10915-10916	×	_
72-13	10917-10918	3	_
72-14	10919-10920	×	_
72-15	10921-10922	3	_
72-16	10923-10926	mm3	_
72-17	10927-10929	to	_
72-18	10930-10935	match	_
72-19	10936-10939	the	_
72-20	10940-10945	voxel	_
72-21	10946-10950	size	_
72-22	10951-10953	of	_
72-23	10954-10957	the	_
72-24	10958-10962	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
72-25	10963-10969	images	_
72-26	10970-10972	we	_
72-27	10973-10981	acquired	_
72-28	10982-10987	after	_
72-29	10988-11001	preprocessing	_
72-30	11002-11003	(	_
72-31	11004-11007	Fig	_
72-32	11008-11009	.	_

73-1	11010-11011	1	_
73-2	11012-11013	)	_
73-3	11014-11015	.	_

74-1	11016-11026	Functional	_
74-2	11027-11039	connectivity	_
74-3	11040-11051	calculation	_
74-4	11052-11057	Based	_
74-5	11058-11060	on	_
74-6	11061-11064	the	_
74-7	11065-11072	defined	_
74-8	11073-11076	ROI	_
74-9	11077-11078	,	_
74-10	11079-11081	we	_
74-11	11082-11092	calculated	_
74-12	11093-11103	voxel-wise	_
74-13	11104-11113	bilateral	_
74-14	11114-11121	insular	_
74-15	11122-11132	functional	_
74-16	11133-11145	connectivity	_
74-17	11146-11150	maps	_
74-18	11151-11154	for	_
74-19	11155-11159	each	_
74-20	11160-11167	subject	_
74-21	11168-11178	throughout	_
74-22	11179-11182	the	_
74-23	11183-11188	whole	_
74-24	11189-11194	brain	_
74-25	11195-11196	.	_

75-1	11197-11202	These	_
75-2	11203-11213	functional	_
75-3	11214-11218	maps	_
75-4	11219-11223	were	_
75-5	11224-11234	calculated	_
75-6	11235-11237	by	_
75-7	11238-11247	computing	_
75-8	11248-11251	the	_
75-9	11252-11259	Pearson	_
75-10	11260-11262	's	_
75-11	11263-11274	correlation	_
75-12	11275-11286	coefficient	_
75-13	11287-11294	between	_
75-14	11295-11298	the	_
75-15	11299-11306	average	_
75-16	11307-11311	BOLD	_
75-17	11312-11316	time	_
75-18	11317-11323	series	_
75-19	11324-11326	in	_
75-20	11327-11330	the	_
75-21	11331-11334	ROI	_
75-22	11335-11338	and	_
75-23	11339-11342	the	_
75-24	11343-11347	time	_
75-25	11348-11354	series	_
75-26	11355-11359	from	_
75-27	11360-11363	all	_
75-28	11364-11367	the	_
75-29	11368-11374	voxels	_
75-30	11375-11381	within	_
75-31	11382-11383	a	_
75-32	11384-11388	gray	_
75-33	11389-11395	matter	_
75-34	11396-11400	mask	_
75-35	11401-11403	of	_
75-36	11404-11407	the	_
75-37	11408-11413	whole	_
75-38	11414-11419	brain	_
75-39	11420-11421	.	_

76-1	11422-11425	The	_
76-2	11426-11438	correlations	_
76-3	11439-11443	were	_
76-4	11444-11455	transformed	_
76-5	11456-11458	to	_
76-6	11459-11460	a	_
76-7	11461-11469	Gaussian	_
76-8	11470-11482	distribution	_
76-9	11483-11488	using	_
76-10	11489-11495	Fisher	_
76-11	11496-11498	's	_
76-12	11499-11515	z-transformation	_
76-13	11516-11517	.	_

77-1	11518-11529	Statistical	_
77-2	11530-11538	analysis	_
77-3	11539-11541	We	_
77-4	11542-11551	performed	_
77-5	11552-11553	a	_
77-6	11554-11566	second-level	_
77-7	11567-11575	analysis	_
77-8	11576-11581	using	_
77-9	11582-11587	SPM12	_
77-10	11588-11589	(	_
77-11	11590-11594	http	_
77-12	11595-11596	:	_
77-13	11597-11625	//www.fil.ion.ucl.ac.uk/spm/	_
77-14	11626-11627	)	_
77-15	11628-11632	with	_
77-16	11633-11636	the	_
77-17	11637-11645	subjects	_
77-18	11646-11648	in	_
77-19	11649-11652	the	_
77-20	11653-11656	two	_
77-21	11657-11668	independent	_
77-22	11669-11677	datasets	_
77-23	11678-11679	,	_
77-24	11680-11690	separately	_
77-25	11691-11692	.	_

78-1	11693-11695	We	_
78-2	11696-11703	applied	_
78-3	11704-11705	a	_
78-4	11706-11714	multiple	_
78-5	11715-11725	regression	_
78-6	11726-11731	model	_
78-7	11732-11735	and	_
78-8	11736-11746	voxel-wise	_
78-9	11747-11753	t-test	_
78-10	11754-11756	to	_
78-11	11757-11761	test	_
78-12	11762-11765	for	_
78-13	11766-11777	significant	_
78-14	11778-11790	correlations	_
78-15	11791-11798	between	_
78-16	11799-11802	the	_
78-17	11803-11808	PGRSs	_
78-18	11809-11812	and	_
78-19	11813-11816	the	_
78-20	11817-11827	voxel-wise	_
78-21	11828-11838	functional	_
78-22	11839-11851	connectivity	_
78-23	11852-11853	.	_

79-1	11854-11857	Age	_
79-2	11858-11859	,	_
79-3	11860-11863	sex	_
79-4	11864-11865	,	_
79-5	11866-11869	and	_
79-6	11870-11873	the	_
79-7	11874-11875	3	_
79-8	11876-11879	top	_
79-9	11880-11889	principle	_
79-10	11890-11900	components	_
79-11	11901-11905	were	_
79-12	11906-11914	included	_
79-13	11915-11917	in	_
79-14	11918-11921	the	_
79-15	11922-11927	model	_
79-16	11928-11930	as	_
79-17	11931-11941	covariates	_
79-18	11942-11943	.	_

80-1	11944-11946	To	_
80-2	11947-11954	correct	_
80-3	11955-11958	for	_
80-4	11959-11967	multiple	_
80-5	11968-11979	comparisons	_
80-6	11980-11981	,	_
80-7	11982-11984	an	_
80-8	11985-11993	Alphasim	_
80-9	11994-12003	algorithm	_
80-10	12004-12015	implemented	_
80-11	12016-12018	in	_
80-12	12019-12023	REST	_
80-13	12024-12027	was	_
80-14	12028-12035	applied	_
80-15	12036-12037	.	_

81-1	12038-12049	Statistical	_
81-2	12050-12054	maps	_
81-3	12055-12059	were	_
81-4	12060-12071	thresholded	_
81-5	12072-12074	at	_
81-6	12075-12076	a	_
81-7	12077-12088	voxel-level	_
81-8	12089-12091	of	_
81-9	12092-12093	p	_
81-10	12094-12095	<	_
81-11	12096-12100	0.05	_
81-12	12101-12104	and	_
81-13	12105-12112	cluster	_
81-14	12113-12117	size	_
81-15	12118-12119	>	_
81-16	12120-12122	90	_
81-17	12123-12129	voxels	_
81-18	12130-12132	to	_
81-19	12133-12138	reach	_
81-20	12139-12140	a	_
81-21	12141-12154	cluster-level	_
81-22	12155-12167	significance	_
81-23	12168-12170	of	_
81-24	12171-12176	alpha	_
81-25	12177-12178	<	_
81-26	12179-12183	0.05	_
81-27	12184-12185	.	_

82-1	12186-12191	After	_
82-2	12192-12202	correcting	_
82-3	12203-12206	for	_
82-4	12207-12215	multiple	_
82-5	12216-12227	comparisons	_
82-6	12228-12229	,	_
82-7	12230-12232	we	_
82-8	12233-12242	conducted	_
82-9	12243-12254	conjunction	_
82-10	12255-12263	analyses	_
82-11	12264-12265	.	_

83-1	12266-12271	First	_
83-2	12272-12274	we	_
83-3	12275-12284	performed	_
83-4	12285-12286	a	_
83-5	12287-12298	conjunction	_
83-6	12299-12307	analysis	_
83-7	12308-12310	to	_
83-8	12311-12315	find	_
83-9	12316-12326	consistent	_
83-10	12327-12337	functional	_
83-11	12338-12350	connectivity	_
83-12	12351-12362	alterations	_
83-13	12363-12373	associated	_
83-14	12374-12378	with	_
83-15	12379-12393	cross-disorder	_
83-16	12394-12398	PGRS	_
83-17	12399-12406	between	_
83-18	12407-12412	these	_
83-19	12413-12416	two	_
83-20	12417-12425	datasets	_
83-21	12426-12427	.	_

84-1	12428-12432	Then	_
84-2	12433-12435	we	_
84-3	12436-12445	conducted	_
84-4	12446-12453	another	_
84-5	12454-12457	two	_
84-6	12458-12469	conjunction	_
84-7	12470-12478	analyses	_
84-8	12479-12481	to	_
84-9	12482-12486	find	_
84-10	12487-12504	disorder-specific	_
84-11	12505-12515	functional	_
84-12	12516-12528	connectivity	_
84-13	12529-12540	alterations	_
84-14	12541-12542	,	_
84-15	12543-12548	first	_
84-16	12549-12559	performing	_
84-17	12560-12561	a	_
84-18	12562-12573	conjunction	_
84-19	12574-12582	analysis	_
84-20	12583-12586	for	_
84-21	12587-12591	each	_
84-22	12592-12599	dataset	_
84-23	12600-12602	to	_
84-24	12603-12607	find	_
84-25	12608-12625	disorder-specific	_
84-26	12626-12636	functional	_
84-27	12637-12649	connectivity	_
84-28	12650-12661	alterations	_
84-29	12662-12665	and	_
84-30	12666-12670	then	_
84-31	12671-12681	conducting	_
84-32	12682-12685	the	_
84-33	12686-12692	second	_
84-34	12693-12704	conjunction	_
84-35	12705-12713	analysis	_
84-36	12714-12716	to	_
84-37	12717-12721	find	_
84-38	12722-12732	consistent	_
84-39	12733-12750	disorder-specific	_
84-40	12751-12761	functional	_
84-41	12762-12774	connectivity	_
84-42	12775-12783	patterns	_
84-43	12784-12788	with	_
84-44	12789-12792	the	_
84-45	12793-12802	bilateral	_
84-46	12803-12809	insula	_
84-47	12810-12812	in	_
84-48	12813-12817	both	_
84-49	12818-12826	datasets	_
84-50	12827-12828	.	_

85-1	12829-12837	Clusters	_
85-2	12838-12844	larger	_
85-3	12845-12849	than	_
85-4	12850-12852	10	_
85-5	12853-12859	voxels	_
85-6	12860-12864	were	_
85-7	12865-12873	retained	_
85-8	12874-12875	.	_

86-1	12876-12880	Then	_
86-2	12881-12883	to	_
86-3	12884-12888	find	_
86-4	12889-12896	whether	_
86-5	12897-12902	PGRSs	_
86-6	12903-12913	calculated	_
86-7	12914-12919	using	_
86-8	12920-12925	other	_
86-9	12926-12936	thresholds	_
86-10	12937-12944	produce	_
86-11	12945-12952	similar	_
86-12	12953-12960	results	_
86-13	12961-12962	,	_
86-14	12963-12965	we	_
86-15	12966-12975	conducted	_
86-16	12976-12979	the	_
86-17	12980-12984	same	_
86-18	12985-12993	analysis	_
86-19	12994-12996	as	_
86-20	12997-13002	above	_
86-21	13003-13008	using	_
86-22	13009-13013	PGRS	_
86-23	13014-13024	calculated	_
86-24	13025-13029	with	_
86-25	13030-13032	PT	_
86-26	13033-13034	<	_
86-27	13035-13039	0.01	_
86-28	13040-13041	,	_
86-29	13042-13045	0.1	_
86-30	13046-13049	and	_
86-31	13050-13053	0.5	_
86-32	13054-13064	separately	_
86-33	13065-13066	,	_
86-34	13067-13070	but	_
86-35	13071-13075	only	_
86-36	13076-13087	considering	_
86-37	13088-13091	the	_
86-38	13092-13103	significant	_
86-39	13104-13110	voxels	_
86-40	13111-13113	at	_
86-41	13114-13116	PT	_
86-42	13117-13118	<	_
86-43	13119-13123	0.05	_
86-44	13124-13125	,	_
86-45	13126-13129	not	_
86-46	13130-13133	the	_
86-47	13134-13140	voxels	_
86-48	13141-13143	in	_
86-49	13144-13147	the	_
86-50	13148-13153	whole	_
86-51	13154-13159	brain	_
86-52	13160-13161	.	_

87-1	13162-13164	To	_
87-2	13165-13172	correct	_
87-3	13173-13176	for	_
87-4	13177-13185	multiple	_
87-5	13186-13197	comparisons	_
87-6	13198-13199	,	_
87-7	13200-13202	an	_
87-8	13203-13211	Alphasim	_
87-9	13212-13221	algorithm	_
87-10	13222-13233	implemented	_
87-11	13234-13236	in	_
87-12	13237-13241	REST	_
87-13	13242-13245	was	_
87-14	13246-13253	applied	_
87-15	13254-13255	.	_

88-1	13256-13267	Statistical	_
88-2	13268-13272	maps	_
88-3	13273-13277	were	_
88-4	13278-13289	thresholded	_
88-5	13290-13292	at	_
88-6	13293-13294	a	_
88-7	13295-13306	voxel-level	_
88-8	13307-13309	of	_
88-9	13310-13311	p	_
88-10	13312-13313	<	_
88-11	13314-13318	0.05	_
88-12	13319-13322	and	_
88-13	13323-13330	cluster	_
88-14	13331-13335	size	_
88-15	13336-13337	>	_
88-16	13338-13340	12	_
88-17	13341-13347	voxels	_
88-18	13348-13351	for	_
88-19	13352-13358	autism	_
88-20	13359-13360	,	_
88-21	13361-13362	9	_
88-22	13363-13369	voxels	_
88-23	13370-13373	for	_
88-24	13374-13376	BD	_
88-25	13377-13380	and	_
88-26	13381-13382	7	_
88-27	13383-13389	voxels	_
88-28	13390-13393	for	_
88-29	13394-13407	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
88-30	13408-13410	to	_
88-31	13411-13416	reach	_
88-32	13417-13418	a	_
88-33	13419-13432	cluster-level	_
88-34	13433-13445	significance	_
88-35	13446-13448	of	_
88-36	13449-13454	alpha	_
88-37	13455-13456	<	_
88-38	13457-13461	0.05	_
88-39	13462-13463	.	_

